TargetMol

Mivobulin Isethionate

Product Code:
 
TAR-T28048
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28048-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Mivobulin is a tubulin inhibitor potentially for the treatment of glioma, malignant melanoma, prostate, ovarian cancer. CI-980 acts at the colchicine-binding site.
CAS:
126268-81-3
Formula:
C19H25N5O6S
Molecular Weight:
451.5
Purity:
0.98
SMILES:
OCCS(O)(=O)=O.CCOC(=O)Nc1cc2N[C@@H](C)C(=Nc2c(N)n1)c1ccccc1

References

1. Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WK. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002;20(7-8):948-54. PubMed PMID: 12449727. 2. Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD; Ohio State University Phase II Research Consortium Study.. A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study. Cancer Invest. 2002;20(2):192-8. PubMed PMID: 11901539. 3. Whitehead RP, Unger JM, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Invest New Drugs. 2001;19(3):239-43. PubMed PMID: 11561681. 4. Ryan CW, Shulman KL, Richards JM, Kugler JW, Sosman JA, Ansari RH, Vokes EE, Vogelzang NJ. CI-980 in advanced melanoma and hormone refractory prostate cancer. Invest New Drugs. 2000 May;18(2):187-91. PubMed PMID: 10857996.